Cost-savings for the NHS
Find out how much your locality could save with STADA UK’s respiratory portfolio, compared to your current usage by requesting a tailored cost savings report.

For use in adults only.
Asthma
Proxor® 100/6 and 200/6: Regular treatment of asthma where use of a combination product is appropriate: Patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled rapid-acting β2-agonist; Patients already adequately controlled on both inhaled corticosteroids and long-acting β2-agonists.
Chronic Obstructive Pulmonary Disease (COPD)
Proxor® 100/6: Symptomatic treatment of severe COPD (FEV1 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators. Proxor® 100/6 is licensed for Maintenance and Reliever Therapy (MART) in asthma.
Proxor® prescribing information is available here

Trokide Vertical-Haler® is indicated as a maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD).
Trokide® prescribing information is available here

Fixkoh Airmaster® is indicated in adults and adolescents 12 years of age and older.
Asthma
In the regular treatment of asthma where use of a combination product (long-acting β2 agonist and inhaled corticosteroid is appropriate. In patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β2 agonist, or, patients already adequately controlled on both inhaled corticosteroid and long-acting β2 agonist. Note: Fixkoh Airmaster® 50 microgram/100 micrograms is not appropriate in adults and children with severe asthma.
Chronic Obstructive Pulmonary Disease (COPD)
For the symptomatic treatment of patients with COPD, with a FEV1 < 60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.
Fixkoh® prescribing information is available here
Find out how much your locality could save with STADA UK’s respiratory portfolio, compared to your current usage by requesting a tailored cost savings report.
We are dedicated to measuring and reducing carbon emissions across our respiratory medicines portfolio on an ongoing basis, aiming to achieve to become net-zero by 2045.
The information in this website is intended solely for UK Healthcare Professionals and contains promotional information.
I confirm I am a UK Healthcare Professional
UK Patients – If you have been prescribed one of our products by a UK healthcare professional, you can visit the dedicated patient sites for more information: Trokide® | Proxor® | Fixkoh®
Other visitors – Please visit our main web site.
UK-MULT-307(1) | July 2025
The information in this website is intended solely for UK Healthcare Professionals and contains promotional information.
I confirm I am a UK Healthcare Professional
UK Patients – If you have been prescribed one of our products by a UK healthcare professional, you can visit the dedicated patient sites for more information: Trokide® | Proxor® | Fixkoh®
Other visitors – Please visit our main web site.
UK-MULT-307(1) | July 2025
The information in this website is intended solely for UK Healthcare Professionals and contains promotional information.
I confirm I am a UK Healthcare Professional
UK Patients – If you have been prescribed one of our products by a UK healthcare professional, you can visit the dedicated patient sites for more information: Trokide® | Proxor® | Fixkoh®
Other visitors – Please visit our main web site.
UK-MULT-307(1) | July 2025
The information in this website is intended solely for UK Healthcare Professionals and contains promotional information.
I confirm I am a UK Healthcare Professional
UK Patients – If you have been prescribed one of our products by a UK healthcare professional, you can visit the dedicated patient sites for more information: Trokide® | Proxor® | Fixkoh®
Other visitors – Please visit our main web site.
UK-MULT-307(1) | July 2025
For use in adults only.
Asthma
Proxor® 100/6 and 200/6: Regular treatment of asthma where use of a combination product is appropriate: Patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled rapid-acting β2-agonist; Patients already adequately controlled on both inhaled corticosteroids and long-acting β2-agonists.
Chronic Obstructive Pulmonary Disease (COPD)
Proxor® 100/6: Symptomatic treatment of severe COPD (FEV1 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators. Proxor® 100/6 is licensed for Maintenance and Reliever Therapy (MART) in asthma.
Trokide Vertical-Haler® is indicated as a maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD).
Fixkoh Airmaster® is indicated in adults and adolescents 12 years of age and older.
Asthma
In the regular treatment of asthma where use of a combination product (long-acting β2 agonist and inhaled corticosteroid is appropriate. In patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β2 agonist, or, patients already adequately controlled on both inhaled corticosteroid and long-acting β2 agonist. Note: Fixkoh Airmaster® 50 microgram/100 micrograms is not appropriate in adults and children with severe asthma.
Chronic Obstructive Pulmonary Disease (COPD)
For the symptomatic treatment of patients with COPD, with a FEV1 < 60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.
The website you are going to is maintained by a third party over whom Thornton & Ross Limited has no control or responsibility. We have provided this link as an appropriate resource to our visitors but Thornton & Ross Limited is not responsible for the content or information on this site.
UK-MULT-307l | April 2025